The Technical Analyst
Select Language :
Cullinan Oncology, LLC [CGEM]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Cullinan Oncology, LLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Cullinan Oncology, LLC is listed at the  Exchange

-3.89% $17.04

America/New_York / 28 mar 2024 @ 16:00


Cullinan Oncology, LLC: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 733.84 mill
EPS: -3.69
P/E: -4.62
Earnings Date: May 08, 2024
SharesOutstanding: 43.07 mill
Avg Daily Volume: 0.425 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Neutral
DE: Sell
P/E: Strong Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -4.62 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.79x
Company: PE -4.62 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$2.28
(-86.60%) $-14.76
Date: 2024-03-28
Expected Trading Range (DAY)

$ 15.99 - 18.05

( +/- 6.04%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-22 Savill Corrine Buy 37 500 Common Stock
2024-02-22 Savill Corrine Buy 75 000 Stock Option (Right to Buy)
2024-02-22 Ahmed Nadim Buy 320 000 Stock Option (Right to Buy)
2024-02-22 Ahmed Nadim Buy 160 000 Common Stock
2024-02-22 Trigilio Jeffrey Buy 50 000 Common Stock
INSIDER POWER
-16.82
Last 99 transactions
Buy: 3 151 716 | Sell: 6 781 307

Forecast: 16:00 - $17.04

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $17.04
Forecast 2: 16:00 - $17.04
Forecast 3: 16:00 - $17.04
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $17.04 (-3.89% )
Volume 0.372 mill
Avg. Vol. 0.425 mill
% of Avg. Vol 87.52 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Cullinan Oncology, LLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Cullinan Oncology, LLC

RSI

Intraday RSI14 chart for Cullinan Oncology, LLC

Last 10 Buy & Sell Signals For CGEM

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$17.88N/AActive
Profile picture for
            Cullinan Oncology, LLC

CGEM

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date Signal @
PROUSDMar 28 - 21:08$2.26
LEOUSDMar 28 - 21:086.03
ICPUSDMar 28 - 21:06$18.06
SANTOSUSDMar 28 - 20:587.76
FXSUSDMar 28 - 20:59$7.71
KUBUSDMar 28 - 20:582.77
KCSUSDMar 28 - 20:58$12.06
BCHUSDMar 28 - 21:00$568.09
STRAXUSDMar 28 - 20:55$0.141
ETHUPUSDMar 28 - 20:5534.44

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.